1. Home
  2. RBB vs ALLO Comparison

RBB vs ALLO Comparison

Compare RBB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBB
  • ALLO
  • Stock Information
  • Founded
  • RBB 2008
  • ALLO 2017
  • Country
  • RBB United States
  • ALLO United States
  • Employees
  • RBB N/A
  • ALLO N/A
  • Industry
  • RBB Major Banks
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RBB Finance
  • ALLO Health Care
  • Exchange
  • RBB Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • RBB 288.8M
  • ALLO 277.8M
  • IPO Year
  • RBB 2017
  • ALLO 2018
  • Fundamental
  • Price
  • RBB $18.35
  • ALLO $1.26
  • Analyst Decision
  • RBB Hold
  • ALLO Strong Buy
  • Analyst Count
  • RBB 4
  • ALLO 9
  • Target Price
  • RBB $21.25
  • ALLO $8.44
  • AVG Volume (30 Days)
  • RBB 82.0K
  • ALLO 3.3M
  • Earning Date
  • RBB 07-21-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • RBB 3.49%
  • ALLO N/A
  • EPS Growth
  • RBB N/A
  • ALLO N/A
  • EPS
  • RBB 1.17
  • ALLO N/A
  • Revenue
  • RBB $98,305,000.00
  • ALLO N/A
  • Revenue This Year
  • RBB $15.58
  • ALLO N/A
  • Revenue Next Year
  • RBB $8.35
  • ALLO $199.63
  • P/E Ratio
  • RBB $15.71
  • ALLO N/A
  • Revenue Growth
  • RBB N/A
  • ALLO N/A
  • 52 Week Low
  • RBB $14.40
  • ALLO $0.86
  • 52 Week High
  • RBB $25.30
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • RBB 58.43
  • ALLO 53.64
  • Support Level
  • RBB $17.74
  • ALLO $1.21
  • Resistance Level
  • RBB $18.94
  • ALLO $1.31
  • Average True Range (ATR)
  • RBB 0.49
  • ALLO 0.08
  • MACD
  • RBB -0.02
  • ALLO 0.01
  • Stochastic Oscillator
  • RBB 70.06
  • ALLO 76.86

About RBB RBB Bancorp

RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: